Q2FY23 Financial Summary and Strategic Highlights

Medical Surgical Portfolio growth drivers Over the next 12 - 18 months Surgical Innovations Surgical procedures are moving from open to minimally invasive along with innovation advancements in advanced energy and stapling; Continuing to address acute supply chain issues, and ongoing management of China VBP Hugo TM RAS System 14 Investor Meetings | November 2022 Signia™ Powered Stapler V-Loc TM Wound Closure Device Barbed Sonicision™ 7mm Sutures GI & Patient Monitoring P Investing in long term pipeline; Patient Monitoring received 510(k) clearance for the RespArray™ monitor, which includes Nellcor™ pulse ox technology Nellcor™ OxySoft Pulse Ox Sensor 80 991 20 20/80- RespArrayTM Monitor Gl Genius TM Surgical Robotics Entering surgical robotics market as second meaningful player; market highly underpenetrated due to cost and utilization barriers Limited market release of our Hugo TM RAS system continues, combined with our Touch Surgery TM Enterprise Al and image capturing platform; leverages our MIS instrument expertise; customer demand is high Expanding market access through regulatory approvals, including recent CE Mark clearance and Health Canada license to expand indication for General Surgery and MHLW approval for Uro/GYN in Japan, the 3rd largest RAS market in the world today First procedure for U.S. IDE urology clinical trial anticipated in the calendar year LAPAROSC CHOLECYSTECTOMY Touch Surgery™ Enterprise DS1 Medtronic

View entire presentation